Journal
European Urology
Publication Date
2016
Volume
70
Issue
5
Inclusive Pages
875-883
Document Type
Open Access Publication
DOI
10.1016/j.eururo.2016.06.002
Rights and Permissions
Parker C, Finkelstein SE, Michalski JM, et al (2016) Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial. European Urology, 70(5):875-883. https://doi.org/10.1016/j.eururo.2016.06.002 Copyright 2016 European Association of Urology. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Recommended Citation
Parker, Christopher; Finkelstein, Steven E.; Michalski, Jeff M.; O'Sullivan, Joe M.; Bruland, Oyvind; Vogelzang, Nicholas J.; Coleman, Robert E.; Nilsson, Sten; Sartor, Oliver; Li, Rui; Seger, Monica A.; and Bottomley, David, "Efficacy and safety of radium-223 dichloride in symptomatic castration-resistant prostate cancer patients with or without baseline opioid use from the phase 3 ALSYMPCA trial." European Urology. 70, 5. 875-883. (2016).
https://digitalcommons.wustl.edu/open_access_pubs/6511
Supplemental Fig. 1 - Kaplan-Meier estimate of time to first use of EBRT for bone pain (ITT population; N = 921).
1-s2.0-S030228381630272X-mmc2.docx (15 kB)
Supplemental Table 1 - Best standard of care administered to ALSYMPCA patientsa (ITT Population; N = 921)
